On Dec. 20^th, 2012, Zensun finished patient recruitment for US Phase II clinical trial of anti-heart failure drug—rhNRG-1. On Feb 20^th, Zensun unblinded the clinical data which showed an excellent consistency with Chinese Phase II clinical results. It means the successful Chinese clinical results of rhNRG-1 have been confirmed by US clinical trial. And it is a solid step for Zensun to put this innovative drug on global pharmaceutical market.